Thursday, July 29

ensayos

Covid 19, dosis, ensayos, España, Noticias, pruebas, Salud, vacunacion, vacunas

Spain seeks paid volunteers to test its vaccines | Digital Trends Spanish

Two organizations related to the field of health in Spain are looking for volunteers to test the vaccines they develop for COVID-19. The Higher Center for Scientific Research (CSIC) is looking for people who want to be part of the trial of the CSIC-Biofabric vaccine, which has shown 100 percent efficacy in mice. For these tests, people between 18 and 39 years old who are not vaccinated and who have not been infected with coronavirus are needed. Meanwhile, the Girona Institute for Biomedical Research has published a statement calling on the public to test the Hipra vaccine, which plans to produce about 400 million doses of the drug Hipra SARS-CoV-2 during the next year. In this case, those who sign up as volunteers will receive remuneration for taking both doses. In addition, they will ...
ensayos, gripe, gripe estacional, Moderna, Noticias, Salud, vacuna

Moderna begins trials of a flu vaccine | Digital Trends Spanish

Moderna has announced that its quadrivalent seasonal flu mRNA candidate vaccine has begun clinical trials. The pharmaceutical company reported that it administered its vaccine to the first group of volunteers in a clinical trial, marking the next stage of the company's work in these types of technologies after the success of its ani-COVID-19 vaccine. The efficacy of mRNA vaccines against coronavirus represented an important support for this type of drug. Now, drug companies plan to use this technology to fight other types of infectious diseases, including the flu. Moderna hopes that mRNA-based flu vaccines will be more effective than traditional ones. Being faster to manufacture, production would not have to start that far in advance and could theoretically be better suited to the typ...
ensayos, Fase I, Noticias, pruebas, Reino Unido, Salud, SIDA, Universidad de Oxford, vacuna, vih

Oxford University Starts HIV Vaccine Trials | Digital Trends Spanish

Researchers at the University of Oxford began phase I trials of a novel vaccine targeting a "wide range" of HIV variants. The HIV-CORE 0052 trial is part of the European AIDS Vaccine Initiative, and will involve 13 healthy, HIV-negative adults between 18 and 65 years of age, who are not considered to be at high risk of infection. Thus, participants will receive a dose of the vaccine, known as HIVconsvC, followed by another booster dose at four weeks. How does it work? Unlike other vaccine candidates, HIVconsvX is designed to induce immune system T lymphocytes and target highly conserved and vulnerable regions of HIV. “An effective vaccine against HIV has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy both in HIV-negative ind...
cáncer, canceres, coctel de drogas, drogas, enfermedad, ensayos, inmunoterapia, laboratorio, medicamentos, Noticias, pacientes, pruebas clinicas, quimioterapia, respuesta inmune, Salud, tratamiento

A new cocktail of drugs to treat aggressive cancers | Digital Trends Spanish

A team of researchers from the Harvard Wyss Institute claims to have developed a method to treat triple negative breast cancer. Professionals believe that by mixing immunotherapy with chemotherapy they may have developed a method for the specific treatment of aggressive cancers. Chemotherapy is essentially a poison that is injected into the body and kills cancer cells. However, it also causes enormous collateral damage to the surrounding tissue. Immunotherapy, for its part, tries to squeeze the immune response that exists in the patient so that it targets cancer cells. However, the more aggressive cancers trigger immunosuppressive responses in the area near the tumors, making both treatments less effective. For the same reason, the researchers took the best of both approaches, mix...
clinicos, Covid 19, efectos asociados, Efectos secundarios, ensayos, inyeccion, laboratorio, Noticias, Pfizer, prueba, Salud, vacuna, vacuna pfizer, vacunacion

What are the side effects of the Pfizer vaccine? | Digital Trends Spanish

More than 43,500 people from six countries have participated in the phase three trials of the pharmaceutical company Pfizer for its coronavirus vaccine. An article from Daily Mail compiles the testimonies of some volunteers who explain what are the main side effects associated with the vaccine. A 45-year-old volunteer noted that the first dose left her with side effects similar to those caused by the flu shot, but that symptoms were more severe after the second dose. Another 44-year-old volunteer claimed that the Pfizer vaccine made him feel like he had a severe hangover, but explained that the symptoms disappeared quickly. A third woman, a publicist from Missouri, said that with the first dose of the vaccine she suffered a headache, fever and discomfort all over her body; however...
Brasil, China, coronavac, coronavirus, Covid 19, efectos secundarios fatales, ensayos, Noticias, paciente, paralizacion, pruebas, Salud, sinovac, sinovac biotech, suspensión, vacuna, vacuna china, vacunas, voluntario

Brazil suspends trials of Chinese vaccine against COVID-19 | Digital Trends Spanish

Brazil's National Health Surveillance Agency (Anvisa) suspended phase 3 clinical trials of a candidate vaccine against COVID-19 developed by China. The agency decided to stop the tests after a volunteer suffered "a serious incident" during the clinical trial of the CoronaVac vaccine. Although Anvisa did not provide further details about what happened, it assured that these incidents could include death, possibly fatal side effects, serious disability, hospitalization, in addition to other clinically significant events. For its part, the Chinese laboratory Sinovac Biotech said in a statement that it was confident in the safety of its antidote, in addition to ruling out that the incident was related to it. This situation took the Butantan Institute, the public body that coordinates v...
aspirina, coagulos, coronavirus, Covid 19, cuarentena, ensayos, hospital, Noticias, pandemia, prueba, pulmones, Salud, sangre, tratamiento

Aspirin to get COVID-19 patients back? | Digital Trends Spanish

Several studies have shown that almost 80% of patients who die due to COVID-19 have thrombosis or blood clotting in the lungs. A group of researchers believe that blood thinners, such as aspirin, could help prevent this critical clotting that can lead to the death of a person. For this reason, they will begin to give aspirin to patients infected with coronavirus who are recovering in a British hospital, as part of a trial that seeks to determine if this drug can prevent deadly blood clotting in the lungs. If its effectiveness can be proven, it would be the first over-the-counter drug that has actually been shown to have an impact on the coronavirus. "Aspirin is a very available and inexpensive drug, and if it worked, it would be a huge boost for treatment," says Oxford University p...
Anticuerpos, computacional, computador, contagiados, coronavirus, covid, desarrollo, enfermos, ensayos, escuela de medicina, Noticias, ratones, rescuperados, respuesta, Salud, SARS-CoV-2, ultra potente, Universidad, vacuna

A vaccine against COVID-19 developed on a computer | Digital Trends Spanish

An international team led by researchers from the University of Washington (UW) developed an ultra-potent experimental vaccine to reduce the spread of COVID-19. It is a vaccine based on self-assembled nanoparticles built with computer technology from the UW School of Medicine, that is, they were designed on a computer. The vaccine produces neutralizing antibodies to the virus in mice at levels ten times higher than those seen in people who have recovered from a COVID-19 infection. The vaccine also showed good B cell results after immunization, which may end up being key to immune memory and a longer lasting effect of the vaccine. "We hope that our nanoparticle platform can help fight this pandemic that is causing so much damage to our world," explained Neil King, professor of bioch...
contagios, Covid 19, cura, efectiva, ensayos, espera, Farmacéuticas, hallazgo, laboratorios, Noticias, pandemia, Salud, tiempo, vacuna

WHO reiterates that it will take time to find a cure for COVID-19 | Digital Trends Spanish

The whole world is closely following the present of the different laboratories that are developing an effective vaccine against COVID-19. It is an attitude that is understood, taking into account the alarming increase in the number of deaths from this cause in recent days in Europe. Many are impatient because the pandemic does not give respite and some of the pharmaceutical companies working on a cure have made statements that call for optimism. However, from the World Health Organization (WHO) they prefer to be cautious and lower expectations in relation to the time it will take for a vaccine to be ready. "It will be time before we have a safe and effective COVID-19 vaccine - in any population group - and even longer before it is available to a large number of people," said an age...
clinicos, coronavirus, Covid 19, ensayos, londres, Noticias, pacientes, pruebas, Salud, SARS-CoV-2, vacuna, vacunas, voluntarios

Human Challenge: voluntary infection for COVID-19 vaccines | Digital Trends Spanish

The entire planet maintains a fierce fight against COVID-19. The pandemic caused by this disease looms as one of the greatest health threats we have faced in recent times. At this point, with more than a million deaths globally, any attempt to slow the spread of the virus is worth it, even if it includes intentionally infecting some volunteer patients. Scientists from Imperial College have proposed a controversial and disputed method of deliberate exposure, known as the test "Human challenge ". According to experts, this strategy would include deliberately infecting a group of volunteer patients in early 2021, to study how vaccinated people respond to being exposed to the virus. This could accelerate the discovery of an effective coronavirus vaccine and make a difference to the wa...